Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
Jun 23, 2014
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 ( O nce-daily R
Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
Jun 03, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") announced that it has received the $5 million milestone payment from Grifols S.A. for the dosing of the first patient in the ORBIT-3 ( O nce-daily R espiratory B ronchiectasis I nhalation T
FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic
May 20, 2014
Pulmaquin designated as a QIDP for Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Chronic Lung Infections with Pseudomonas aeruginosa HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced that the U.S.
Aradigm Announces First Quarter 2014 Financial Results
May 14, 2014
Completion of Royalty Assignment Eliminates All Debt HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2014 . Total revenue was $6.6 million for the first quarter of
Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
Apr 30, 2014
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM.OB) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-3 ( O nce-daily
Results from Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2014 International Conference
Apr 15, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Scientists from the Oregon State University , Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the "Company") demonstrated that after 4 days of in vitro treatment of macrophages infected with Mycobacterium avium and Mycobacterium abscessus , Aradigm's
Aradigm Announces Fourth Quarter 2013 and Full Year Financial Results
Mar 13, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013 . Fourth Quarter 2013 Results The Company recorded $4.6 million in revenue in the fourth quarter of 2013 compared
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014 on February 11
Feb 04, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 16 th Annual BIO CEO & Investor Conference 2014 on Tuesday, February 11, 2014 , at 10:30 a.m. ET .
Aradigm to Present at Biotech Showcase 2014 on January 14
Jan 08, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at Biotech Showcase 2014 on Tuesday, January 14, 2014 , at 11: 30 a.m. Pacific time.
Aradigm Announces Appointment of Dr. Juergen Froehlich as Chief Medical Officer
Nov 19, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company") today announced that Juergen Froehlich , MD has been appointed as Aradigm's Chief Medical Officer. He joins Aradigm from Vertex Pharmaceuticals where he was Head of Regulatory Affairs, overseeing
Aradigm Announces Third Quarter 2013 Financial Results
Oct 28, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2013 . Total revenue was approximately $4.6 million for the third quarter of 2013 compared with revenue of
Aradigm Announces Changes to Its Board of Directors
Sep 18, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") today announced changes to its Board of Directors, including the retirement of Frank Barker and the appointment of Lafmin Morgan and David Bell . Mr.
Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
Sep 16, 2013
INDIANAPOLIS & HAYWARD, Calif. --(BUSINESS WIRE)-- Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc. ), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and
Aradigm to Present at the Stifel Nicolaus 2013 Healthcare Conference
Sep 09, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Nancy E. Pecota , Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2013 Healthcare Conference at the Four Seasons
Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin®
Aug 28, 2013
Aradigm's Proprietary Inhaled Antibiotic for the Chronic Therapy of Patients with Severe Respiratory Disease is Advancing Into Phase III BARCELONA, Spain & HAYWARD, Calif. --(BUSINESS WIRE)-- Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols") and Aradigm Corporation (OTC BB:ARDM.OB)
Aradigm Announces Second Quarter 2013 Financial Results
Aug 08, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2013 . Total revenue was approximately $0.2 million for both the second quarter of 2013 and the second quarter of 2012.
Aradigm Awarded NIH Grant to Investigate New Methods of Diagnoses of Aspirations of Gastrointestinal Contents into the Respiratory Tract with Scientists at UC San Francisco
Aug 07, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- The National Heart, Lung, and Blood Institute , National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux
Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Pulmaquin and Lipoquin
Aug 01, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the treatment of pulmonary non-tuberculous
Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. to Develop and Commercialize Pulmaquin
Jul 16, 2013
Aradigm's Proprietary Inhaled Ciprofloxacin Formulation is a Potential New Therapy for Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") today announced that the Company's shareholders approved all
Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™
May 21, 2013
Aradigm's Proprietary Inhaled Ciprofloxacin Formulation is a Potential New Therapy for Patients with Severe Respiratory Disease BARCELONA, Spain & HAYWARD, Calif. --(BUSINESS WIRE)-- Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols") and Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm")
Displaying 61 - 80 of 234
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.